The global critical care drugs market is estimated at USD 1.22 billion in 2025 and is projected to reach USD 1.91 billion by 2034, growing at a CAGR of 5.11%. Growth is driven by the rising prevalence of chronic diseases, an aging global population, and increasing surgical procedures requiring intensive care medications.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Critical Care Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Critical Care Drugs Market Revenue and Volume, By Drug Type
8.1.1 Opioids
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Morphine
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Pethidine
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Naloxone
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Fentanyl
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Benzodiazepines
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Diazepam
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Midazolam
8.1.8.1. Market Revenue and Volume Forecast
8.1.9. Lorazepum
8.1.9.1. Market Revenue and Volume Forecast
8.1.10. Flumazenil
8.1.10.1. Market Revenue and Volume Forecast
8.1.11. Sedatives
8.1.11.1. Market Revenue and Volume Forecast
8.1.12. Anesthetics
8.1.12.1. Market Revenue and Volume Forecast
8.1.13. Others
8.1.13.1. Market Revenue and Volume Forecast
9.1. Critical Care Drugs Market Revenue and Volume, By End-user
9.1.1. Intensive Care Unit (ICU)
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Coronary Care Unit (CCU)
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Operation Theatres
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Trauma Centers
9.1.4.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Drug Type
10.1.2. Market Revenue and Volume Forecast, By End-user
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Drug Type
10.1.3.2. Market Revenue and Volume Forecast, By End-user
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Drug Type
10.1.4.2. Market Revenue and Volume Forecast, By End-user
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Drug Type
10.2.2. Market Revenue and Volume Forecast, By End-user
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Drug Type
10.2.3.2. Market Revenue and Volume Forecast, By End-user
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Drug Type
10.2.4.2. Market Revenue and Volume Forecast, By End-user
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Drug Type
10.2.5.2. Market Revenue and Volume Forecast, By End-user
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Drug Type
10.2.6.2. Market Revenue and Volume Forecast, By End-user
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Drug Type
10.3.2. Market Revenue and Volume Forecast, By End-user
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Drug Type
10.3.3.2. Market Revenue and Volume Forecast, By End-user
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Drug Type
10.3.4.2. Market Revenue and Volume Forecast, By End-user
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Drug Type
10.3.5.2. Market Revenue and Volume Forecast, By End-user
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Drug Type
10.3.6.2. Market Revenue and Volume Forecast, By End-user
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Drug Type
10.4.2. Market Revenue and Volume Forecast, By End-user
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Drug Type
10.4.3.2. Market Revenue and Volume Forecast, By End-user
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Drug Type
10.4.4.2. Market Revenue and Volume Forecast, By End-user
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Drug Type
10.4.5.2. Market Revenue and Volume Forecast, By End-user
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Drug Type
10.4.6.2. Market Revenue and Volume Forecast, By End-user
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Drug Type
10.5.2. Market Revenue and Volume Forecast, By End-user
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Drug Type
10.5.3.2. Market Revenue and Volume Forecast, By End-user
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Drug Type
10.5.4.2. Market Revenue and Volume Forecast, By End-user
11.1. Pfizer Inc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Abbott
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cadila Pharmaceutica
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cambrex Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Triveni Chemicals
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Haffkine Bio-Pharmaceutical Corporation Ltd
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Neon Laboratories Limited
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description